Basket Trials: Just the End of the First Quarter.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Why we do what we do. A brief analysis of cancer therapies.EXCLI journal · 2020
   Review
2. Secretome profiling identifies neuron-derived neurotrophic factor as a tumor-suppressive factor in lung cancer.JCI insight · 2019
   Article
3. Systems proteogenomics for precision oncology.Oncotarget · 2019
   Article
4. Tissue-specific tumorigenesis: context matters.Nature reviews. Cancer · 2017
   Review
5. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.Annals of oncology : official journal of the European Society for Medical Oncology · 2017
   Review

Corrections and comments

• Commented on by
  Reply to A. Stenzinger et al.2015
• Comment on
  Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.2015

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as